JCNN News Summaries - Japan Corporate News Network - Novartis Pharma Adds High-Dose Tablet to Its Antihypertensive
The following untitled letters were issued by Center for Food Safety and Nutrition’s (CFSAN) Division of Dietary Supplement Programs Office of Nutritional Products or by Center for Drug Evaluation and Research’s Office of Medical Policy Division of Drug Marketing, Advertising and Communications (DDMAC). Copies of the letters are available to subscribers from RECORD-RETRIEVE for $7 plus retrieval.
4LifeResearch, Sandy, UT, Nov. 1 (CFSAN).
Related Results
Novartis claims R$1.1mil profit for 2003.
Diovan(R) (Valsartan) the First Blood Pressure Medication in a Large-Scale Cl…
Novartis lures consumers with value-based program
Novartis’ sales on track in third quarter; profits rise 7% as Diovan, Gleevec…
New hope for soccer ace’s dad
CFSAN reviewed the company’s website and determined it was promoting its products 4Life Transfer Factor GluCoach, BioGenistein Plus and …
Read the rest of this article with a Free Trial at HighBeam Research.
